Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT03302234 2023-09-26

KEYNOTE-598

Phase 3 Completed

568 enrolled 20 charts

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03639714 2023-09-13

A Study of a Personalized Neoantigen Cancer Vaccine

Phase 1/2 Completed

29 enrolled

GastrointestinalGenitourinaryThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms

NCT03953235 2023-09-13

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Phase 1/2 Completed

39 enrolled

GastrointestinalThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03408587 2023-05-06

CLEVER

Phase 1 Completed

11 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Uveal Melanoma, Coxsackievirus Infections, Virus Diseases

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Phase 3 Terminated

481 enrolled 22 charts

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

Clinical Trials

eVOLVE-RCC02

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

IT-01

KEYNOTE-598

A Study of a Personalized Neoantigen Cancer Vaccine

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

CLEVER

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma